Drug Profile
Vobarilizumab - Ablynx
Alternative Names: ALX 0061Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ablynx
- Class Antirheumatics; Proteins
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Rheumatoid arthritis
Highest Development Phases
- Discontinued Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 12 Apr 2021 Discontinued - Phase-I for Rheumatoid arthritis (In volunteers) in Netherlands (IV) before April 2021 (Ablynx website, April 2021)
- 12 Apr 2021 Discontinued - Phase-I for Rheumatoid arthritis (In volunteers) in Netherlands (SC) before April 2021 (Ablynx website, April 2021)
- 12 Apr 2021 Discontinued - Phase-I/II for Rheumatoid arthritis (Treatment-experienced) in Hungary, Poland, Czech Republic (IV) before April 2021 (Ablynx website, April 2021)